Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 391 to 405 of 641 results for prescribing

  1. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

  2. Decision-making:- What interventions, systems and processes are effective and cost effective in changing health and social care practitioners' decision-making and ensuring appropriate antimicrobial stewardship?

    point-of-care tests in decision-making is clinically and cost effective when prescribing antimicrobials in children, young people and...

  3. Service models for withdrawal interventions: What service models are most effective in supporting withdrawal from medicines associated with dependence and withdrawal symptoms?

    Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Number NG215 Date

  4. Cognitive behavioural therapy (CBT) to support withdrawal from benzodiazepines: What is the most effective model of CBT, including timing of CBT, to support withdrawal from benzodiazepines?

    Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Number NG215 Date

  5. Acupuncture to support withdrawal from opioids: What is the clinical and cost effectiveness of acupuncture (including electroacupuncture) as an adjunct to aid withdrawal from opioids?

    Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Number NG215 Date

  6. Multicomponent withdrawal interventions: What are the key components of an effective multicomponent intervention to support dose reduction during withdrawal of opioids?

    Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Number NG215 Date

  7. Withdrawal interventions for gabapentinoids: What are the most clinically and cost-effective strategies or interventions to aid withdrawal of gabapentinoids?

    Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Number NG215 Date

  8. Psychological interventions to support withdrawal: What are the most effective psychological interventions to support withdrawal and help people cope with withdrawal symptoms?

    Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Number NG215 Date

  9. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

  10. Aids to support withdrawal: What is the effectiveness of equipment, technologies, practical aids and medicine formulations in supporting people to manage dose reductions, compared with usual practice?

    Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Number NG215 Date

  11. Information for family members or carers: What information and support are needed by family members or carers of people having treatment with an opioid, benzodiazepine, Z‑drug, antidepressant or gabapentinoid?

    Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Number NG215 Date

  12. Converting to a medicine with a different half‑life to aid withdrawal: What is the clinical and cost effectiveness of converting to medicines with a longer half‑life to aid withdrawal from benzodiazepines or antidepressants?

    Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Number NG215 Date

  13. Multimorbidity: clinical assessment and management (NG56)

    This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.

  14. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.